About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Discover the potential of GLP-1 medications like Ozempic and Mounjaro in treating a wide range of conditions, from diabetes to addiction.

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

GLP-1 medications—like Ozempic, Wegovy, and Zepbound—can help you shed pounds, but only if taken properly. Don't get caught ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

(Reuters) - WW International, also known as WeightWatchers, said on Friday CEO Sima Sistani was stepping down and that insider Tara Comonte would succeed her on an interim basis.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

The company's shares have plummeted about 90 percent this year due to the rising popularity of GLP-1 drugs like Ozempic and ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...